Johnson & Johnson’s $2.2 billion settlement for marketing drugs for unapproved uses and giving kickbacks to doctors has resulted in a payment of $168 million to the whistleblowers who revealed the fraud.
This whistleblower award is one of the largest in history.
The $2.2 million was paid for improper marketing of Risperdal to doctors and nursing homes as treatment for elderly patients with dimentia, when it was only FDA approved for treatment of schizophrenia.
The $168 million includes $112 million for whistleblowers in Pennsylvania, nearly $28 million for whistleblowers in Massachusetts and $28 million for whistleblowers in California, the Justice Department said.
